US equities |
NVDA $239.77 ▲+2.49% SPCX $169.49 ▲+6.62% MU $1,062.56 ▼-1.15% TSLA $379.69 ▲+2.46% SNDK $1,702.09 ▼-1.04% MSFT $527.89 ▲+2.00% INTC $116.12 ▼-2.69% META $742.55 ▲+1.99%
FinancialContent

Tarsus Pharmaceuticals, Inc. - Common Stock (NQ:TARS)

74.50 +1.50 (+2.05%)
Delayed Quote Updated: 3:43 PM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tarsus Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Tarsus Plans to Present 11 Abstracts Highlighting New Insights in Demodex Blepharitis, Ocular Rosacea and the Real-World Impact of XDEMVY at the American Academy of Optometry 2026 Annual Meeting
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Completes Acquisition of Alkeus Pharmaceuticals, Expanding Leadership in Eye Care
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus (TARS) Q2 2026 Earnings Call Transcript ↗
XDEMVY sales hit $173.9M with 69% growth as Tarsus expands into retinal diseases. 
Via The Motley Fool
Topics Earnings
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Beats Q1 Estimates with Explosive XDEMVY Growth But Stock Slips ↗
Via Chartmill
TARSUS PHARMACEUTICALS INC (NASDAQ:TARS) Passes High-Growth Momentum and Minervini Trend Template Screen ↗
Via Chartmill
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) Q4 2025 Earnings: Revenue Soars on XDEMVY Sales, But Losses Widen ↗
Via Chartmill
News headline image
Tarsus Pharmaceuticals Q2 Earnings Call Highlights ↗
Tarsus Pharmaceuticals (NASDAQ:TARS) reported second-quarter growth in sales of its Demodex blepharitis treatment XDEMVY and announced a pending acquisition of Alkeus Pharmaceuticals, adding late-stage... 
Via MarketBeat
Topics Earnings
News headline image
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline ↗
Tarsus Pharmaceuticals (NASDAQ:TARS) said it has closed its acquisition of iRenix Medical, Inc., adding IRX-101, a late-stage investigational ocular surface antiseptic, to its pipeline as the company... 
Via MarketBeat
News headline image
Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharmaceuticals Stock Drops as Short Seller Alleges Illegal Copay Scheme ↗
Tarsus Pharmaceuticals Inc (NASDAQ:TARS) shares are falling Wednesday. Short-seller Culper Research published a report Wednesday alleging the company's sole commercial product relies on an illegal... 
Via Benzinga
Topics Law Enforcement
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million ↗
Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter ↗
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus (TARS) Q1 2026 Earnings Transcript ↗
Tarsus (TARS) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus Pharma Stock Up 20% as Insider Sells $839K in RSU-Linked Trade ↗
This ophthalmic biotech reported a notable insider sale as it advances treatments for Demodex blepharitis and other eye diseases. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Olema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential? ↗
Olema Pharmaceuticals develops targeted therapies for women's cancers, with a lead program advancing in clinical trials for breast cancer. 
Via The Motley Fool
News headline image
Tarsus to Participate in Upcoming Investor Conferences
From Tarsus Pharmaceuticals, Inc
Via GlobeNewswire
News headline image
Tarsus (TARS) Q4 2025 Earnings Call Transcript ↗
Tarsus (TARS) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 Next >